P320 Comparing faecal elastase, pancreatic enzyme doses, HbA1c and insulin doses in adult cystic fibrosis patients pre- and 6 months postcommencement of Kaftrio®
نویسندگان
چکیده
To evaluate the effect of Kaftrio on units lipase/kg/day, faecal elastase level, HbA1c, insulin doses (primary outcome measures) and weight (secondary measure) after a 6 month period in adult patients with cystic fibrosis (CF). Data was collected for under St Barts CF service that had started Kaftrio, at baseline months compared using paired t-test (p < 0.05). Patients were excluded where confounding factors (e.g. pregnancy, malignancy) or incomplete data sets existed, there known poor adherence to Kaftrio. Of those whose analysed (n = 47), 28 (60%) delta F508 homozygous, 46 (98%) pancreatic insufficient diagnosis CFRD. 17 (36%) female 30 (64%) male. Median time frame collection starting 7 (IQR 4). Table 1mean pre post commencement KaftrioPre6 postDifferencep value (paired t-test)Units lipase/kg/day75396762−7770.27Faecal (mcg/gm)1515n/an/aHbAlc (mmol/mol)- CFRD only4949n/an/aDaily fast acting dose (units)12.58.8−3.70.02*significant p 0.05Daily long (units)8.26.8−1.40.45Weight (Kg)62.965.8+2.90.0001**significant 0.001* significant 0.05** 0.001 Open table new tab A reduction daily observed, mean 3.7 per day. There trend towards lipase/kg/day action dose, but these failed reach significance. no change detected HbA1c elastase. gain 2.9 kg (4.6%), line clinical trial data. It is not if effects function insulin/enzyme requirements. The observed cannot solely be attributed improvements function. Further over longer study larger sample size needed.
منابع مشابه
Use of monoclonal faecal elastase-1 concentration for pancreatic status assessment in cystic fibrosis patients.
OBJECTIVE To assess the concentration of faecal elastase-1 (EL-1) in pediatric patients with cystic fibrosis with mutation DeltaF508. METHODS Cross-sectional study with samples collected consecutively from 51 patients aged 4 months to 17 years old (mean 9.11±4.74); 32 (62.8%) patients were male. Clinical-demographic data were collected, as well as data on the type of mutation. Exocrine pancre...
متن کاملPancreatic enzyme supplements in cystic fibrosis.
Approximately 95% of patients in Northern Europe are pancreatic insufficient due to an inadequacy of their own pancreatic enzyme secretions (Littlewood et al, 2006). These patients need to take pancreatic enzyme replacement therapy (PERT) in order to prevent the symptoms of fat malabsorption. These symptoms include frequent pale, oily and offensive stools, abdominal pain, poor growth and defici...
متن کاملFaecal elastase-1 (EL-1) in pediatric patients with cystic fibrosis.
I have read the recent publication on faecal elastase-1 (EL-1) in pediatric patients with cystic fibrosis with great interest.1 Gonzales et al. concluded that “The test was standardized, is easy to execute, and can be used to assess the pancreatic status of patients with cystic fibrosis.”1 There are, however, some concerns. First, no complete study on the diagnostic properties (sensitivity, spe...
متن کاملNutritional Assesment in Cystic Fibrosis Patients( Iran and Newzeland)
Introduction: Patients with Cystic Fibrosis have increased risk of malnutrition. Early detection of nutritional deterioration enables prompt intervention and correction. The aims of this project were to: - Define the nutritional status of CF patients in Iran and New Zealand - Compare and contrast the MacDonald Nutritional Screening tool with the Australasian guidelines for Nutrition in Cyst...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cystic Fibrosis
سال: 2023
ISSN: ['1569-1993', '1873-5010']
DOI: https://doi.org/10.1016/s1569-1993(23)00690-2